Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AstraZeneca

Amgen stock popped Tuesday after the biotech company's AstraZeneca-partnered asthma treatment succeeded in a Phase 3 test. The post Amgen, AstraZeneca Stocks Pop On 'Best-Case' Outcome For Asthma Drug appeared first on Investor's Business Daily.

Amgen, AstraZeneca Stocks Pop On 'Best-Case' Outcome For Asthma Drug

Alexion Pharma

Bayer AG

Regeneron Pharmaceuticals

Sanofi

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable appeared first on Investor's Business Daily.

These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable

THOUSAND OAKS, Calif., Nov. 9, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared...

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

Amgen Inc. (AMGN) Management Presents at Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)

THOUSAND OAKS, Calif., Nov. 9, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that data from its cardiovascular (CV) portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2020: A Virtual Experience, Nov. 13-17, 2020. Amgen will present new...

Amgen Showcases New Data Across Cardiovascular Portfolio At AHA Scientific Sessions 2020: A Virtual Experience

Discovery

eBay

Macerich

Merck

Pfizer

Simon Property Group

Our call of the day offers up several stocks that busy, distracted investors have been overlooking. Smead Capital Management's CIO says they are stocks to hold for the long run.

Need to Know: These 7 unloved stocks are for the long haul, says contrarian manager

THOUSAND OAKS, Calif., Nov. 4, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 29th Annual Credit Suisse Virtual Healthcare Conference at 4:15 p.m. ET on Monday, Nov. 9, 2020, in Scottsdale, Ariz. Murdo Gordon, executive vice president of Global Commercial Operations at Amgen...

Amgen To Present At The 29th Annual Credit Suisse Healthcare Conference

Anthem

Biogen

Cigna

Johnson & Johnson

Eli Lilly

UnitedHealth Group

Shares of UnitedHealth Group Inc. soared 10.2% in morning trading, enough to pace the Dow Jones Industrial Average's gainers, as the uncertain election outcome is seen as a boon to the health care sector. The stock's price gain of $32.65 was adding about 215 points to the Dow's price, while the Dow was up 547 points, or 2.0%.

Health care stocks soar, add more than 350 points to the Dow's price

Bristol-Myers

Amgen and Bristol Myers Squibb have both drawn heavy criticism for their pricing practices.

Is Drug Pricing Backlash a Serious Risk for Big Pharma Stocks?

Visa

Visa is growing payment volumes again, and Amgen reported a double-digit sales increase.

Dow Jones Rebounds as Visa and Amgen Report Strong Results

Amgen (AMGN) beats Q3 estimates for both earnings and sales. It slightly narrows its previously issued sales guidance for 2020 while raising its earnings range.

Amgen (AMGN) Q3 Earnings Top, Prolia, Biosimilars Drive Sales

Amgen (AMGN) is trading lower after third quarter earnings and could drop another 20 points in coming weeks.

Amgen (AMGN) Losing Altitude Despite Strong Quarter

Without the purchase of the blockbuster autoimmune disease drug, Amgen's latest results wouldn't have looked nearly as good.

Thank Otezla for Amgen's Q3 Revenue and Earnings Beats

Amgen Inc. (AMGN) CEO Robert Bradway on Q3 2020 Results - Earnings Call Transcript

Amgen (AMGN) delivered earnings and revenue surprises of 16.53% and 0.65%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates

Amgen posted third-quarter earnings and sales that beat Wall Street views and hiked it earnings outlook, and Amgen stock rose after hours after hitting four-month lows in the regular session. The post Amgen Earnings, Sales Top Wall Street Views; Hikes Earnings Guidance appeared first on Investor's Business Daily.

Amgen Earnings, Sales Top Wall Street Views; Hikes Earnings Guidance

Shares of Amgen (NASDAQ:AMGN) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share increased 19.40% over the past year to $4.37, which beat the estimate of $3.80.

Recap: Amgen Q3 Earnings

Gilead Sciences

Amgen Inc. (NASDAQ: AMGN) and Gilead Sciences Inc.

These Two Major Biotechs Are Bouncing Back With Q3 Results

Amgen Inc on Wednesday said its third-quarter adjusted profit rose 17% due to stronger sales of drugs including the osteoporosis treatment Prolia and recently-acquired psoriasis medication Otezla.

Osteoporosis drug helps Amgen third-quarter profit beat estimates

Amgen Inc. AMGN shares rose in the extended session Wednesday after the biotech drug maker topped Wall Street estimates for the quarter. Amgen shares advanced 1.2% after hours, following a 3.2% decline in the regular session to close at $216.38.

Amgen stock rises after earnings beat

THOUSAND OAKS, Calif., Oct. 28, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2020. Key results include: Total revenues increased 12% to $6.4 billion in comparison to the third quarter of 2019 driven by higher volume growth, partially...

Amgen Reports Third Quarter 2020 Financial Results

AbbVie

bluebird bio

Mustang Bio

Vertex Pharmaceuticals

Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.

7 Cutting-Edge Biotech Stocks for Tomorrow 

THOUSAND OAKS, Calif., Oct. 27, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Wednesday, October 28, 2020, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the...

Amgen Announces Webcast Of 2020 Third Quarter Financial Results

THOUSAND OAKS, Calif., Oct. 27, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has completed trial design discussions through two Complex Innovative Trial Designs (CID) Pilot Program meetings with the U.S. Food and Drug Administration (FDA) for its planned Phase 2...

Amgen Announces Participation Of Systemic Lupus Erythematosus (SLE) Adaptive Clinical Trial In The FDA Complex Innovative Trial Designs (CID) Pilot Program

Novavax

Marketed products -- and work in the pipeline -- should translate into future growth for these shares.

News for Amgen Stock (AMGN)